Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up study for KOI2-002 in dystrophic epidermolysis bullosa
jRCT2080224722Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jun 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of redasemtide in dystrophic epidermolysis bullosa (DEB), sponsored by Shionogi & Co., Ltd. Started Jun 2019; status: completed.
02
Drugs
redasemtide
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on jRCT2080224722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224722.